| scholarly article | Q13442814 |
| P50 | author | Richard B S Roden | Q87305927 |
| Kirill Kalnin | Q95980530 | ||
| P2093 | author name string | John T Schiller | |
| Patricia M Day | |||
| Subhashini Jagu | |||
| Jeffrey Almond | |||
| Lihua Shen | |||
| Yanhua Yan | |||
| Harold Kleanthous | |||
| Victor Costa | |||
| Neil Christensen | |||
| Robert Sabharwal | |||
| Stephen F Anderson | |||
| Svetlana Stegalkina | |||
| Timothy Tibbitts | |||
| P2860 | cites work | Structural basis of TLR5-flagellin recognition and signaling | Q24628830 |
| Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 | Q27860674 | ||
| The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5 | Q28185796 | ||
| Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines | Q28246307 | ||
| Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women | Q28251260 | ||
| Immunogenicity and efficacy of flagellin-fused vaccine candidates targeting 2009 pandemic H1N1 influenza in mice | Q28743887 | ||
| Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs. | Q30369510 | ||
| Superior efficacy of a recombinant flagellin:H5N1 HA globular head vaccine is determined by the placement of the globular head within flagellin. | Q30379493 | ||
| Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments | Q34021545 | ||
| The structure of the TLR5-flagellin complex: a new mode of pathogen detection, conserved receptor dimerization for signaling | Q34262635 | ||
| Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. | Q34417608 | ||
| Optimization of multimeric human papillomavirus L2 vaccines | Q34576677 | ||
| Preclinical model to test human papillomavirus virus (HPV) capsid vaccines in vivo using infectious HPV/cottontail rabbit papillomavirus chimeric papillomavirus particles | Q35185992 | ||
| Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine. | Q35277985 | ||
| A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection | Q35599310 | ||
| Sensitivity of in situ detection with biotinylated probes of human papilloma virus type 16 DNA in frozen tissue sections of squamous cell carcinomas of the cervix. | Q35818781 | ||
| A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies | Q36086265 | ||
| Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. | Q36314993 | ||
| A protective and broadly cross-neutralizing epitope of human papillomavirus L2. | Q36315086 | ||
| Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. | Q36545925 | ||
| On regulation of phagosome maturation and antigen presentation | Q36598303 | ||
| Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine | Q36827128 | ||
| Expression and immunogenicity of a streptococcal M protein epitope inserted in Salmonella flagellin | Q36965479 | ||
| Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates | Q37051021 | ||
| Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus | Q37099713 | ||
| Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation | Q37213042 | ||
| Declining genital Warts in young women in england associated with HPV 16/18 vaccination: an ecological study | Q37213048 | ||
| TLR-mediated stimulation of APC: Distinct cytokine responses of B cells and dendritic cells. | Q37235039 | ||
| Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis | Q38037763 | ||
| The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years | Q38383523 | ||
| Efficacy of a vaccine that links viral epitopes to flagellin in protecting aged mice from influenza viral infection. | Q38678908 | ||
| Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults | Q39744811 | ||
| A universal epitope-based influenza vaccine and its efficacy against H5N1. | Q39988803 | ||
| Generation of HPV pseudovirions using transfection and their use in neutralization assays. | Q40340652 | ||
| Activation of innate immunity, inflammation, and potentiation of DNA vaccination through mammalian expression of the TLR5 agonist flagellin. | Q40376275 | ||
| In situ localization of human papilloma virus type 16 DNA in a metastasis of an endocervical adenocarcinoma | Q41826995 | ||
| Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial | Q42257816 | ||
| Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years | Q43452461 | ||
| Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection | Q45107740 | ||
| Regulation of phagosome maturation by signals from toll-like receptors | Q47604798 | ||
| Immune response to cholera toxin epitope inserted in Salmonella flagellin | Q50195562 | ||
| Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types. | Q51805351 | ||
| Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. | Q52956682 | ||
| Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI). | Q54361083 | ||
| Chemotherapy for bladder cancer | Q79347014 | ||
| Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin | Q80155644 | ||
| The value of HPV vaccination | Q83194126 | ||
| P433 | issue | 28 | |
| P407 | language of work or name | English | Q1860 |
| P1104 | number of pages | 8 | |
| P304 | page(s) | 3540-3547 | |
| P577 | publication date | 2014-04-26 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes | |
| P478 | volume | 32 |
| Q55215825 | A Dual-Type L2 11-88 Peptide from HPV Types 16/18 Formulated in Montanide ISA 720 Induced Strong and Balanced Th1/Th2 Immune Responses, Associated with High Titers of Broad Spectrum Cross-Reactive Antibodies in Vaccinated Mice. |
| Q92858730 | A rationally designed flagellin-L2 fusion protein induced serum and mucosal neutralizing antibodies against multiple HPV types |
| Q60909641 | Application of built-in adjuvants for epitope-based vaccines |
| Q36240497 | Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV) |
| Q55054189 | Cutaneous Papillomaviruses and Non-melanoma Skin Cancer: Causal Agents or Innocent Bystanders? |
| Q52729536 | DNA Vaccine-Encoded Flagellin Can Be Used as an Adjuvant Scaffold to Augment HIV-1 gp41 Membrane Proximal External Region Immunogenicity. |
| Q39021001 | Developments in L2-based human papillomavirus (HPV) vaccines |
| Q52312756 | Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice. |
| Q28603888 | Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes |
| Q61817646 | Exploring the Papillomaviral Proteome to Identify Potential Candidates for a Chimeric Vaccine against Cervix Papilloma Using Immunomics and Computational Structural Vaccinology |
| Q41926367 | Human papillomavirus 16L1-58L2 chimeric virus-like particles elicit durable neutralizing antibody responses against a broad-spectrum of human papillomavirus types |
| Q35532771 | Identification of Broad-Genotype HPV L2 Neutralization Site for Pan-HPV Vaccine Development by a Cross-Neutralizing Antibody |
| Q38640038 | Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes |
| Q40490973 | Lipidated L2 epitope repeats fused with a single-chain antibody fragment targeting human FcγRI elicited cross-neutralizing antibodies against a broad spectrum of human papillomavirus types |
| Q38460209 | Next generation prophylactic human papillomavirus vaccines |
| Q35744303 | Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2 |
| Q37014047 | Progress and prospects for L2-based human papillomavirus vaccines |
| Q39036718 | Recent advances in preclinical model systems for papillomaviruses |
| Q58375482 | Using vaccine Immunostimulation/Immunodynamic modelling methods to inform vaccine dose decision-making |
Search more.